Episode 69. ASH 2025 Lymphoma Roundup with Dr. Carla Casulo

BloodCancerTalks: ASH 2025 Lymphoma Roundup

Guest: Dr. Carla Casulo, Associate Professor, Wilmot Cancer Centre, University of Rochester

Abstracts Discussed

Follicular Lymphoma

EPCORE-FL1 (Falchi) - Epcoritamab plus lenalidomide-rituximab (R2) in relapsed/refractory FL

Theme: Bispecific antibody combinations in R/R FL; comparing to other approaches

Diffuse Large B-Cell Lymphoma (DLBCL) - Elderly/Unfit Patients

MorningSun (Sharman) - Mosunetuzumab monotherapy in patients ≥80 years or chemo-ineligible

EPCOR-DLBCL-3 (Vitolo) - Epcoritamab monotherapy in elderly patients

R-Pola-Glo - Rituximab-polatuzumab-glofitamab combination in older/frail patients

Theme: Single-agent and combination bispecific strategies for elderly and frail DLBCL patients

DLBCL - First-Line Treatment

SMART STOP (Westin) - Chemotherapy-free approach using lenalidomide, tafasitamab, rituximab, acalabrutinib (ULTRA regimen)

FrontMIND - Tafasitamab-lenalidomide added to R-CHOP

Theme: Chemotherapy-sparing and chemo-intensification strategies in newly diagnosed DLBCL

DLBCL - Relapsed/Refractory

DALY 2-EU (Borchmann) - Dual CD19/CD20 CAR-T (zamto-cel) versus R-GemOx in transplant-ineligible patients

Theme: Expanding CAR-T eligibility; treatment selection in transplant-ineligible R/R DLBCL

Hodgkin Lymphoma

SWOG 1826 - 3-year update: Nivolumab-AVD versus brentuximab-AVD

HD21 - 5-year update: PET-adapted BrECADD versus BEACOPP

Theme: Long-term outcomes and treatment selection in newly diagnosed Hodgkin lymphoma

Burkitt Lymphoma

ZUMA-25 (Van Dorp) - Brexucabtagene autoleucel (Brexu-cel) in relapsed/refractory Burkitt

Theme: CAR-T therapy for the challenging population of R/R Burkitt lymphoma

Mantle Cell Lymphoma - First-Line

TrAVeRse - Acalabrutinib, venetoclax, rituximab

GLOVe - Glofitamab, lenalidomide, venetoclax (high-risk MCL)

BOVen - Zanubrutinib, obinutuzumab, venetoclax (older patients)

MAVO - Acalabrutinib, venetoclax, obinutuzumab

Window-3 - Acalabrutinib-rituximab followed by brexu-cel (high-risk MCL)

Theme: Chemotherapy-free combinations in newly diagnosed mantle cell lymphoma